Pennsylvania
Retatrutide
Buy Retatrutide in Pennsylvania: Triple-Action Weight Loss
PA residents can access the most advanced weight loss medication through TRIMI.
Last updated: April 1, 2026•8 min read
Retatrutide targets three hormone receptors for up to 24% body weight loss -- surpassing semaglutide and tirzepatide. Pennsylvania residents can access compounded retatrutide through TRIMI telehealth, from Philadelphia to Pittsburgh and beyond.
Triple-Action
GLP-1
Appetite suppression, slowed digestion.
GIP
Insulin sensitivity, fat metabolism.
Glucagon
Energy expenditure, fat burning.
Comparison
| Medication | Receptors | Weight Loss |
|---|---|---|
| Semaglutide | 1 | 15-17% |
| Tirzepatide | 2 | 20-22% |
| Retatrutide | 3 | Up to 24% |
PA Access
- • Telehealth statewide
- • 3-7 day delivery
- • Philly, Pittsburgh, all PA
- • Licensed compounding
Getting Started
- Online health assessment
- Virtual PA-licensed provider consultation
- Custom retatrutide protocol
- Home delivery
Medical Disclaimer
Informational only. Retatrutide is investigational. Requires provider evaluation. Side effects: nausea, vomiting, diarrhea.
Explore Retatrutide in PA
Most advanced weight loss treatment. Talk to a PA provider today.
Explore OptionsMore on state guides
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).